Navigation Links
Leading the Site CTMS Market: Clinical Conductor CTMS Reaches 1,600 Sites
Date:8/29/2013

ROCHESTER, N.Y., Aug. 29, 2013 /PRNewswire/ -- Bio-Optronics, the developer of Clinical Conductor Site CTMS, is thrilled to announce the successful CTMS implementation at over 1,600 clinical research sites around the world, making it the most widely used clinical trial management system. Designed specifically for research sites, Clinical Conductor Site CTMS is the premier tool for clinical research sites.

Sites that have adopted the Clinical Conductor Site CTMS platform have seen dramatic improvements in their overall operational effectiveness; many sites have reported up to a 20% increase in overall efficiency, while showing a 30% increase in profitability while using the software.

Company Vice President and COO Maria Durkin states, "Clinical Conductor Site CTMS has revolutionized the way sites conduct trials. Our customers are meeting recruitment targets more quickly, improving financial performance and managing trial documentation efficiently.  Sites using Clinical Conductor are also differentiating themselves as successful research organizations that consistently meet deliverables and achieve results. We've seen our customers achieve significant growth in trials. We are proud to be working with them and appreciate the ongoing feedback that enables Clinical Conductor Site CTMS to continue to adapt and grow with the market's needs."

Clinical Conductor Site CTMS has helped research sites worldwide make a profound impact on the healthcare industry. Since its debut, Clinical Conductor Site CTMS has been used in nearly 40,000 trials and has tracked over 2 million trial patients, spanning single sites, multi-location sites, site networks and hospital departments. As Clinical Conductor Site CTMS continues to grow, we foresee additional ways in which researchers will be able to expand and optimize their businesses, while expediting delivery of critical new enhancements in medicine, through the use of this CTMS.

Created with the understanding that no two sites are the same, Clinical Conductor Site CTMS has been designed with extensive functionality capable of satisfying every trial management need while adapting to the specific needs of each research organization. Listening to our customers and adapting to their changing needs, coupled with many years of healthcare experience, Clinical Conductor is able to stay on the leading edge when it comes to providing research organizations the necessary tools for successful trial management. The success and experience with site customers has provided Bio-Optronics the knowledge to expand its portfolio with Clinical Conductor Enterprise, a unique CTMS that provides unparalleled project management, visibility and real-time collaboration for CROs, SMOs, AMCs and provider networks managing multiple research trials across multiple sites, research organizations and partners.

Clinical Conductor Site CTMS is the site-specific trial management solution from leading healthcare software and service provider Bio-Optronics. As a market leader with over 28 years of industry experience working with over 1,800 healthcare and life sciences organizations, Bio-Optronics produces a variety of products aimed at meeting the specific needs of each organization: Clinical Conductor Enterprise, a leading-edge CTMS for organizations managing multiple trials across multiple locations; Momentum Physician and Staff Scheduler,  the highly configurable, rule-based scheduling software; and Biopoint, a patient identification system designed to ensure the proper identification of patients and synchronization of treatment at hospitals and other long-term care facilities. Bio-Optronics and its products are recognized for consistent, unparalleled service and support that continuously ensures our products are exceeding client and market needs.

Bio-Optronics, +1 585-272-1960, www.bio-optronics.com; Kyle Ricketts, Marketing Specialist, kricketts@bio-optronics.com 


'/>"/>
SOURCE Bio-Optronics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
2. PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
3. Centius – Partners with Engaged Nation– a Leading Gaming Industry Customer Loyalty Solution Provider to Help Maximize Customer Lifetime Value
4. GeneCell International’s Director of Operations, Jose Cirino, Organizes A Series of Educational Seminars with South Florida's Leading Obstetricians and Gynecologist
5. Medrio, a Leading EDC Provider for Clinical Research, Announces Its Latest Version, 8.1 with iPad Support, is Available Without Charge for Academic Researchers
6. Accel-KKR Makes Growth Equity Investment in Zinc Ahead, Leading Provider of Marketing Compliance Solutions for the Life Sciences Industry
7. Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes
8. Metabolix Executives to Present at Leading Industry Conferences
9. Medical Concierge Travel International launches in Tandem with Leading Medical Cost Containment Company, EME International aimed at Self-Funded and Insurance Companies
10. Alexandrias 499 Illinois Street in Mission Bay, San Francisco, Signs Anchor 97,700 Rentable Square Foot Lease with Leading Mid-Cap Life Science Company
11. Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
(Date:6/20/2016)... , June 20, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... the prisons involved, it has secured the final ... (DOC) facilities for Managed Access Systems (MAS) installed. ... additional facilities to be installed by October, 2016. ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
Breaking Biology News(10 mins):